Feb 26 (Reuters) – Eli Lilly’s experimental weight-loss pill, orforglipron, caused more side effects and treatment discontinuations than Novo Nordisk’s oral semaglutide in a head-to-head diabetes trial, full results showed on Thursday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Anil D’Silva)
Comments